InInflammation, interferon-alpha, and depression

Psychiatric Annals

Volumn 42, Issue 9, 2012, Pages 317-321

  Lotrich, Francis ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867668606     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/00485713-20120906-04     Document Type: Article

References (30)

1. Piser TM. Linking the cytokine and neurocircuitry hypotheses of depression: a translational framework for discovery and development of novel anti-depressants. Brain Behav Immun. 2010;24(4):515-524.
2. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446-457.
3. Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry. 2011;16(7):751-762.
4. van den Biggelaar AHJ, Gussekloo J, de Craen AJM, et al. Inflammation and interleukin-1 signaling network contribute to depressive symptoms but not cognitive decline in old age. Exp Gerontol. 2007;42(7):693-701.
5. Prather AA, Rabinovitz M, Pollock BG, Lotrich FE. Cytokine-induced depression during IFN-α treatment: the role of IL-6 and sleep quality. Brain Behav Immun. 2009;23(8):1109-1116.
6. Miller GE, Cole SW. Clustering of depression and inflammation in adolescents previously exposed to childhood adversity. Biol Psychiatry. 2012;72:34-40.
7. Anisman H. Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci. 2009;34(1):4-20.
8. Konsman JP, Parnet P, Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci. 2002;25(3):154-159.
9. Connor TJ, Song C, Leonard BE, Merali Z, Anisman H. An assessment of the effects of central interleukin-1b,-2,-6, and tumor necrosis factor-a administration on some behavioural, neurochemical, endocrine and immune parameters in the rat. Neuroscience. 1998;84(3):923-933.
10. Maier SF, Nguyen KT, Deak T, Milligan ED, Watkins LR. Stress, learned helplessness, and brain interleukin-1b. Adv Exp Med Biol. 1999;461:235-250.
11. Peng CH, Chiou SH, Chen SJ, Chou YC, Ky HH, Cheng CK. Neuroprotection by imipramine against lipopolysaccharide-induced apoptosis in hippocampus-dreived neural stem cellsmediated by activation of BDNF and the MAPK pathway. Eur Neuropsychopharm. 2008;18:128-140.
12. Koo JW, Russo SJ, Ferguson D, Nestler NJ, Duman RS. Nuclear factor-kb is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Natl Acad Sci U S A. 2010;107:2669-2674.
13. Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001;58:445-452.
14. Lotrich FE. Risk factors and prevention of interferon-induced depression. Dialogues Clin Neurosci. 2009;11(4):417-426.
15. Goldsmith J, Hauser P. Psychiatric issues in patients with hepatitis C. Psychiatr Ann. 2003;33(6):357-360.
16. Hosoda S, Takimura H, Shibayama M, et al. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci. 2000;54:565-572.
17. Schaefer M, Sarkar R, Knop V, et al. Escitalopram for the prevention of peginterferon-alpha-2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease. Ann Intern Med. 2012;157:94-103.
18. Dan AA, Crone C, Wise TN, et al. Anger experiences among hepatitis C patients: relationship to depressive symptoms and health-related quality of life. J Psychosomat Res. 2007;48(3):223-229.
19. Franzen PL, Buysse DJ, Rabinovitz M, Pollock BG, Lotrich FE. Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment. J Psychiatric Res. 2009;177(1-2):240-245.
20. Lotrich FE, Rabinovitz F, Gironda P, Pollock BG. Depression following pegylated interferon-alpha: characteristics and vulnerability. J Psychosomat Res. 2007;63:131-135.
21. Lotrich FE, Ferrell RF, Rabinovitz M, Pollock BG. Labile anger during interferon-alpha treatment is associated with a polymorphism in tumor necrosis factor-alpha. Clin Neuropharmacol. 2010;33(4):191-197.
22. Lotrich FE. Management of psychiatric disease in hepatitis c treatment candidates. Curr Hepat Rep. 2011;9(2):113-118.
23. Kraus MR, Schafer A, Schottker K, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomized, double-blind, placebo-controlled study. Gut. 2008;57:531-536.
24. Nickel T, Sonntag A, Backmund M, Pollmacher T. Depression during therapy with interferon alpha--how long should an antidepressant treatment last? Pharmacopsychiatry. 2005;38(2):102-104.
25. Capuron L, Raison CL, Musselman DL, et al. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry. 2003;160:1342-1345.
26. Bull SJ, Huezo-Diaz P, Binder EB, et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-a and ribavirin treatment. Mol Psychiatry. 2008;14:1095-1104.
27. Lotrich FE, Sears B, McNamara RK. Elevated omega-6/omega-3 fatty acid ratio predicts depression development following interferon-alpha treatment: relationship with interleukin-6. Brain Behav Immun. 2012, in press.
28. Lotrich FE. Inflammatory cytokines, growth factors, and depression. Curr Pharm Des. 2012, In press.
29. Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry. 2009;65(4):344-348.
30. Capuron L, Pagnoni G, Demetrashvili MF, et al. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology. 2007;32(11):2384-2392.